The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.
Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.
This trial was terminated before completion. Termination can indicate safety signals, futility findings, or business/regulatory decisions by the sponsor.
Insmed Incorporated (INSM) is the sponsoring company for this trial. BiotechSign currently grades this company C (56/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.